CompletedEarly Phase 1

Effect of Probenecid on Synovial Fluid ATP Levels in CPPD

United States8 participantsStarted 2014-10-15

Plain-language summary

This study will investigate the hypothesis that probenecid, a medication currently used for gout, reduces levels of ATP in the joint fluid of patients with calcium pyrophosphate deposition disease (CPPD), another common type of crystal-related arthritis. There is good evidence that CPPD results from an excess of ATP in joints. The investigators will measure levels of ATP in joint fluid before and after 5 days of treatment with probenecid. This study will serve to rationalize larger studies of probenecid in CPPD.

Who can participate

Age range21 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \>21 years, * CPPD diagnosed by Ryan /McCarty criteria * Joint effusion in a shoulder or knee Exclusion Criteria: * Inability to sign informed consent * Age \<21 years * History of renal stones * Significant renal dysfunction (CKD \>stage 2) * Blood dyscrasias * Current use of drugs which interact with probenecid * Concurrent gout * Active infection, including bacteremia and overlying cellulitis * Recent joint trauma * Intra-articular corticosteroids in the affected joint within three months

What they're measuring

ATP Levels in Synovial Fluid

Timeframe: 5 days

Trial details

NCT IDNCT02243631

SponsorVA Office of Research and Development

Sponsor typeFED

Study typeINTERVENTIONAL

Primary completion2021-04-08

Results submitted2022-03-24

View on ClinicalTrials.gov More Calcium Pyrophosphate Deposition Disease trials